News und Analysen
![State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
State of Maryland Allows Point-of-Care Testing for COVID-19; Quidel Expands Training Program
Quidel Corporation (NASDAQ: QDEL) (“Quidel”), a provider of rapid diagnostic testing solutions, cellular-based virology assays and molecular diagnostic systems, announced that the State of Maryland
![Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on August 4, 2020 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement
![Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
Simulations Plus Announces Closing of Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Simulations Plus, Inc. (Nasdaq: SLP), a premier developer of drug discovery and development software for modeling and simulation software products and services for the pharmaceutical
![NanoString Technologies Releases Operating Results for Second Quarter of 2020](/assets/news/news1-f26f2455ece0c3cbea64441818e795358cadddddb27e796f883ae2bd06f66139.png)
NanoString Technologies Releases Operating Results for Second Quarter of 2020
NanoString Technologies, Inc. (NASDAQ:NSTG), a leading provider of life science tools for discovery and translational research, today reported financial results for the second quarter of 2020.
![American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Results](/assets/news/news12-a6c8e663da6f66e4f8b76885d84b91bc276bfd92fd8727e9ade1f1d9f4df9b67.png)
American Renal Associates Holdings, Inc. Announces Second Quarter 2020 Results
American Renal Associates Holdings, Inc. (NYSE: ARA) (the “Company”), a leading kidney care and dialysis provider focused on partnering with local nephrologists, today announced financial and
![Dexcom Announces Upcoming Conference Presentation](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Dexcom Announces Upcoming Conference Presentation
DexCom, Inc. (NASDAQ:DXCM) today announced that management will present an update on Dexcom at the following upcoming investor conference:
-
Quentin Blackford, Chief Operating Officer and Chief
![Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Jubilant Radiopharma and Navidea Biopharmaceuticals Sign Binding Memorandum of Understanding for Commercialization Partnership
Jubilant Radiopharma, a business unit of Jubilant Pharma Limited and Navidea Biopharmaceuticals, Inc. (NYSE MKT: NAVB) announced today that both companies have signed a binding memorandum of
![Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Sangamo Therapeutics to Present at the 2020 Wedbush PacGrow Healthcare Conference
Sangamo Therapeutics, Inc. (Nasdaq: SGMO), a genomic medicine company, announced today that Sandy Macrae, CEO of Sangamo, will present at the 2020 Wedbush PacGrow Healthcare Conference on August
![Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Navidea Biopharmaceuticals Signs Binding Framework for Commercialization Partnership with Jubilant Radiopharma
Navidea Biopharmaceuticals, Inc. (NYSE American: NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, is pleased to
![Illumina to Webcast Upcoming Investor Conference Presentation](/assets/news/news7-ff65ae96e2a4b99929975e34f30f51b3393455f312fc86852d9fc8020c5054eb.png)
Illumina to Webcast Upcoming Investor Conference Presentation
Illumina, Inc. (NASDAQ:ILMN) today announced that its executives will be speaking at the following investor conference and invited investors to participate via webcast.
UBS Genomics 2.0 and
![Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Pfizer Announces Agreement with Gilead to Manufacture Remdesivir for Treatment of COVID-19
Pfizer Inc. (NYSE: PFE) today announced a multi-year agreement with Gilead Sciences, Inc. to manufacture and supply Gilead’s investigational antiviral remdesivir, as one of multiple external
![Medigene berichtet über 2. Quartal und veröffentlicht Halbjahresbericht 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Medigene berichtet über 2. Quartal und veröffentlicht Halbjahresbericht 2020
Telefonkonferenz heute, 7. August 2020 um 14.00 Uhr MEZ (in englischer Sprache)
Unternehmensmitteilung für den Kapitalmarkt
Martinsried/München (07.08.2020) - Die Medigene AG (Medigene,
![Medigene provides Q2 update and 6M report 2020](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Medigene provides Q2 update and 6M report 2020
Conference call on 7 August 2020 at 2pm CET (Frankfurt) / 8am EDT (New York)
Business news for the stock market
Martinsried/ Munich (07.08.2020) - Medigene AG (Medigene, FSE: MDG1, Prime
![Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome](/assets/news/news19-14feaf1b3ac689101974b5354f2ab8bb5cb2e7cb49a06b120b8491e9ebba31f4.png)
Illumina Announces the NovaSeqTM 6000 v1.5 Reagent Kit Unlocking Deeper Discoveries with the $600 Genome
Illumina, Inc. (Nasdaq:ILMN). The power to make bigger discoveries is here with the launch of NovaSeqTM 6000 v1.5 Reagent Kit. The new NovaSeq 6000 v1.5 Reagent Kits aim to make whole genome
![Clovis Oncology Announces Second Quarter 2020 Operating Results](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Clovis Oncology Announces Second Quarter 2020 Operating Results
Clovis Oncology, Inc. (NASDAQ:CLVS) reported financial results for the quarter ended June 30, 2020, and provided an update on the Company’s clinical development programs and regulatory and
![Savara Reports Second Quarter 2020 Financial Results and Provides Business Update](/assets/news/news8-29d1d55c755b03e328399113b5bdd004223f995e95194ba5ee80af9da39a41e3.png)
Savara Reports Second Quarter 2020 Financial Results and Provides Business Update
Savara Inc. (Nasdaq: SVRA), an orphan lung disease company, today reported financial results for the second quarter ending June 30, 2020 and provided a business update.
“With a final design for
![Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update](/assets/news/news18-f135f6c168ef56d2b112890081403b0a310104acfadbf4a8f72634bd390e98ac.png)
Navidea Biopharmaceuticals to Host Second Quarter 2020 Earnings Conference Call and Corporate Update
Navidea Biopharmaceuticals, Inc. (NYSE American:NAVB) (“Navidea” or the “Company”), a company focused on the development of precision immunodiagnostic agents and immunotherapeutics, today announced
![Puma Biotechnology Reports Second Quarter 2020 Financial Results](/assets/news/news15-207f60e93f55a63563671c62b1e07d0bc426e50a03c286a608f29c8138f4f1de.png)
Puma Biotechnology Reports Second Quarter 2020 Financial Results
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the second quarter ended June 30, 2020. Unless otherwise stated, all comparisons are for the
![Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020](/assets/news/news13-125fa69a38b6955d740c18f7e750c42a3317f6873eded3044187d2ece3aa0ac7.png)
Illumina Reports Financial Results for Second Quarter of Fiscal Year 2020
Illumina, Inc. (NASDAQ: ILMN) today announced its financial results for the second quarter of fiscal year 2020.
Second quarter 2020 results reflect the impact of the global COVID-19 pandemic:
![Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row](/assets/news/news11-1ebbf8540812dc8f080ecfeb67ce19c492651a7c439bd800cec2630c3a04a840.png)
Humana Ranks #1 for Customer Satisfaction for Mail Order in J.D. Power Pharmacy Study for Third Year in a Row
Humana Pharmacy, a division of Humana Inc. (NYSE: HUM), has been named the best in Mail Order Pharmacy customer satisfaction in the J.D. Power 2020 U.S. Pharmacy Study. It’s the third consecutive
![THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
THERANEXUS : DECLARATION OF TOTAL NUMBER OF SHARES AND VOTING RIGHTS
Lyon, August 6, 2020 – Theranexus, a biopharmaceutical company innovating in the treatment of neurological diseases and pioneer in the development of drug candidates modulating the interaction
![Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020](/assets/news/news10-be520e400538f920c1970757e43cd0aa35625c1095be243829bb7a152346bd95.png)
Pfizer Announces Times for Rescheduled Virtual Investor Day on September 14 and September 15, 2020
Pfizer Inc. (NYSE: PFE) announced today that it will be holding its rescheduled Investor Day virtually over two days: Monday, September 14, 2020 from 1:00 p.m. EDT to approximately 4:00 p.m. EDT
![Chemed Corporation Declares Quarterly Dividend of 34 Cents](/assets/news/news9-b4ba75b613b80e3d047ded18f34335e7f81348578b67aee3f1469440916c031e.png)
Chemed Corporation Declares Quarterly Dividend of 34 Cents
Chemed Corporation (NYSE:CHE) announced today that the Board of Directors has declared a quarterly cash dividend of 34-cents per share on the Company’s capital stock, payable on September 4, 2020
![MorphoSys: Anlegern gefällt der Ausblick nicht, aber...](/assets/news/news2-a19c21d90ec8043c932052617f43da76ea8e48ecd096318e237ea24d69a5c8b8.png)
MorphoSys: Anlegern gefällt der Ausblick nicht, aber...
Erst am vergangenen Wochenende konnte das deutsche Biotechunternehmen MorphoSys (WKN: 663200) einen großen Erfolg verbuchen, nämlich die FDA-Zulassung des Krebsmittels Monjuvi. Daraufhin machte die
![Biofrontera: Die US-Zocker drehen jetzt völlig durch!](/assets/news/news16-82a218458f0e15ae617f9186b258dfd3add112716106c6ee3cbb48563ccdef52.png)
Biofrontera: Die US-Zocker drehen jetzt völlig durch!
Aufgrund der Covid-19-Pandemie bedingten Wirtschaftskrise gibt es in den USA plötzlich ein Sozialsystem. Welch seltsame Blüten dies treibt, zeigt sich nun ausgerechnet beim deutschen